AL001 (latozinemab)

TargetGRN

Modalitymonoclonal antibody (sortilin blocker to raise progranulin)

IndicationFrontotemporal dementia (GRN mutation)

PhasePhase 3 (Discontinued)

PartnerGSK

Trial IDNCT04374136

Notes

INFRONT-3 trial. Latozinemab was designed to raise progranulin levels by blocking sortilin-mediated degradation. The Phase 3 trial was terminated after the drug failed to meet its primary endpoint of slowing disease progression in FTD-GRN patients.

Source

Program entries are factual summaries of publicly disclosed clinical programs. Microglia.ai does not imply predictions about therapeutic outcomes or investment advice.

Last reviewed: June 2, 2026